8-K
filed May 11, 2026, 4:02 PM ET
ticker GRTX
CIK 0001563577
other material
confidence high
sentiment negative
materiality 0.80
Galera shareholders approve reverse split (1:75 to 1:200) and share increase to 400M
Galera Therapeutics, Inc.
- Elected J. Mel Sorensen (Class III), Nancy Chang and Michael Friedman (Class I) as directors.
- Ratified KPMG as auditor for FY 2026.
- Approved say-on-pay and annual frequency for future say-on-pay votes.
- Authorized amendment raising common shares from 200M to 400M.
- Authorized reverse stock split at Board-discretion ratio between 1:75 and 1:200.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Galera Therapeutics, Inc. shareholders approved Advisory Vote on Frequency of Future Say-On-Pay Votes (every one year) at the 2026-05-08 meeting.
- Proposal
- say on pay frequency
- Outcome
- passed
- Meeting
- 2026-05-08
Exact text from the filing
Proposal 4—Advisory Vote on Frequency of Future Say-On-Pay Votes: 1 Year 2 Years 3 Years Abstentions Broker Non-Votes 108,127,837 64,666 3,611,866 1,076,074 10,877,949
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Galera Therapeutics, Inc. shareholders approved Election of Directors at the 2026-05-08 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2026-05-08
Exact text from the filing
At the combined 2025 and 2026 Annual Meeting of Stockholders (the “ Annual Meeting ”) of Galera Therapeutics, Inc. (the “ Company ”) held on May 8, 2026, the Company’s stockholders (i) elected (A) one Class III director to the board of directors of the Company (the “ Board ”), to serve until the Company’s 2028 annual meeting of stockholders and until his successor is duly elected and qualified, and (B) two Class I directors to the Board, each to serve until the Company’s 2029 annual meeting of stockholders and until their respective successors are duly elected and qualified
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Galera Therapeutics, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2026-05-08 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2026-05-08
Exact text from the filing
Proposal 2—Ratification of Appointment of Independent Registered Public Accounting Firm: Votes For Votes Against Abstentions 121,742,195 1,961,191 55,006
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Galera Therapeutics, Inc. shareholders approved Approval of Charter Amendment to Increase Authorized Capital Stock from 200 million shares to 400 million shares at the 2026-05-08 meeting.
- Proposal
- charter amendment
- Outcome
- passed
- Meeting
- 2026-05-08
Exact text from the filing
Proposal 5—Approval of Charter Amendment to Increase Authorized Capital Stock: Votes For Votes Against Abstentions 120,916,020 2,745,505 96,867
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Galera Therapeutics, Inc. shareholders approved Approval of Charter Amendment to Provide Written Consent Right at the 2026-05-08 meeting.
- Proposal
- charter amendment
- Outcome
- passed
- Meeting
- 2026-05-08
Exact text from the filing
Proposal 6—Approval of Charter Amendment to Provide Written Consent Right: Votes For Votes Against Abstentions Broker Non-Votes 112,456,777 417,500 6,166 10,877,949
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Galera Therapeutics, Inc. shareholders approved Approval of Charter Amendment to Effect a Reverse Stock Split at a ratio between 1:75 and 1:200, if and when determined by the Board at the 2026-05-08 meeting.
- Proposal
- reverse split
- Outcome
- passed
- Meeting
- 2026-05-08
Exact text from the filing
Proposal 7—Approval of Charter Amendment to Effect a Reverse Stock Split: Votes For Votes Against Abstentions 121,087,262 2,639,613 31,517
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Galera Therapeutics, Inc. shareholders approved Approval of compensation paid to the Company’s named executive officers (Say-on-Pay) at the 2026-05-08 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2026-05-08
Exact text from the filing
Proposal 3—Say-on-Pay Vote: Votes For Votes Against Abstentions Broker Non-Votes 108,167,385 3,690,210 1,022,848 10,877,949
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.